Compound efflux in Helicobacter pylori.
Susceptibility testing with a variety of structurally unrelated compounds showed that hefC in Helicobacter pylori is involved in multidrug efflux. This efflux was shown to depend on the proton motive force, as demonstrated by ethidium bromide accumulation experiments. Thus, H. pylori contains an active multidrug efflux mechanism.
Infection Discovery, Cancer and Infection Research Area, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, USA.
Amy
A
Kutschke
Boudewijn L M
BL
de Jonge
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics* / Q000378:metabolism; D001692:Biological Transport; D024901:Drug Resistance, Multiple, Bacterial; D004996:Ethidium / Q000378:metabolism; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D018892:Proton-Motive Force
D000900:Anti-Bacterial Agents; D001425:Bacterial Outer Membrane Proteins; D004996:Ethidium